Team of UMass Amherst researchers unveils the latest advance in targeted delivery of therapeutic proteins
May 6, 2021
The advantage of PACs over other therapies. Courtesy: S. Thai Thayumanavan
AMHERST, Mass. – A team of researchers at the Center for Bioactive Delivery at the University of Massachusetts Amherst’s Institute for Applied Life Sciences has engineered a nanoparticle that has the potential to revolutionize disease treatment, including for cancer. This new research, which appears today in “
Angewandte Chemie,”combines two different approaches to more precisely and effectively deliver treatment to the specific cells affected by cancer.
Two of the most promising new treatments involve delivery of cancer-fighting drugs via biologics or antibody-drug conjugates (ADCs). Each has its own advantages and limitations. Biologics, such as protein-based drugs, can directly substitute for a malfunctioning protein in cells. As a result, they have less serious side e
UMass team identifies cancer research breakthrough
Updated May 06, 2021;
Posted May 06, 2021
The University of Massachusetts Amherst Institute for Applied Life Sciences has been a home for research into the treatment of cancer and other diseases, where scientists say they are making a breakthrough. (JIM KINNEY/ THE REPUBLICAN)
Facebook Share
A team of University of Massachusetts Amherst researchers has announced the engineering of a tiny particle it says has the potential to revolutionize disease treatment, including for cancer.
The new research combines two different approaches to more precisely and effectively deliver treatment to the specific cells affected by cancer. The work has been ongoing at the UMass Amherst Institute for Applied Life Sciences, where researchers say a nanoparticle has far-reaching potential.
Biomedical engineer receives NIH Trailblazer grant to advance research on paralysis, brain damage
Imagine harnessing the proliferating power of cancer cells to treat spinal cord injuries and restore function following brain damage. It s an idea that University of Massachusetts Amherst biomedical engineer Chase Cornelison has been exploring in recent years.
Cornelison s research has been deemed so promising that he has earned a National Institutes of Health (NIH) Trailblazer Award. The three-year, $400,000 grant for new and early-stage investigators supports research of high interest to the National Institute of Biomedical Imaging and Engineering and for which no or minimal preliminary data exists.
The
Get Back Massachusetts COVID-19 Testing Project is a collaboration to get an accurate count of individuals infected with COVID-19 over time. The Get Back Mass project will survey and test all randomly selected participants, including those who do not have symptoms. The project will use two home-collected tests: one to test for current COVID-19 infection; and one to test for past COVID-19 infection or vaccination (antibody test). The results will improve our understanding of how COVID-19 has spread across Massachusetts and which communities and populations are most affected. The project aims to enroll about 500 Massachusetts residents per month and will run for about 14-months.
UMass Amherst biomedical engineer awarded NIH Trailblazer grant to advance promising research
May 4, 2021
Created and exported from Biorender.com under a paid subscription.
AMHERST, Mass. – Imagine harnessing the proliferating power of cancer cells to treat spinal cord injuries and restore function following brain damage. It’s an idea that University of Massachusetts Amherst biomedical engineer Chase Cornelison has been exploring in recent years.
Cornelison’s research has been deemed so promising that he has earned a National Institutes of Health (NIH) Trailblazer Award. The three-year, $400,000 grant for new and early-stage investigators supports research of high interest to the National Institute of Biomedical Imaging and Engineering and for which no or minimal preliminary data exists.